Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer

Anticancer Research

Volumn 19, Issue 4 C, 1999, Pages 3549-3552

  Nisman, Benjamin ^a   Amir, Gail ^a   Lafair, Joel ^a   Heching, Norman ^a   Lyass, Olga ^a   Peretz, Tamar ^a   Barak, Vivian ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Adenocarcinoma; CEA; CYFRA 21 1; Large cell carcinoma; NSCLC; Prognosis; Squamous cell carcinoma; TPS

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; TISSUE POLYPEPTIDE ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HISTOPATHOLOGY; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDES; PROGNOSIS; RISK; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033455515     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Strauss GM: Prognostic markers in resectable non-small cell lung cancer. Hematol Oncol Clin North Am 11: 409-434, 1997.
2. Dent PB, McCulloch PB, Wesley-James O, MacLaren R, Muirhead W, Dunnett CW: Measurement of carcinoembryonic antigen in patients with bronchogenic carcinoma. Cancer 42: 1484-1491, 1978.
3. Concannon JP, Dalbow MH, Hodgson SE, Headings JJ, Markopoulos E, Mitchell J, Cushing WJ, Liebler GA: Prognostic value of preoperative carcinoembryonic antigen (CEA) plasma levels in patients with bronchogenic carcinoma. Cancer 42: 1477-1483, 1978.
4. Icard P, Regnard JF, Essomba A, Panebianko V, Magdaleinat P, Levasseur P: Preoperative carcinoembryonic antigen level a prognostic indicator in resected primary lung cancer. Ann Thorac Surg 58: 811-814, 1994.
5. Van der Gaast A, Schoenmakers CHH, Kok TC, Blijenberg BG, Hop WCj, Splinter TAW: Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancer. Eur j Cancer 30A: 1783-1786, 1994.
6. Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, Quoix E: Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest 108: 163-169, 1995.
7. Pujol L, Grenier J, Parrat E, Lehmann M, Lafontaine T, Quantine X, Michel F-B: Cytokeratines as serum tumor markers in lung cancer. A comparison of CYFRA 21-1 and TPS. Am J Respir Crit Care Med 154: 725-733, 1996.
8. Pujol L, Grenier J, Daures JP, Daver A, Pujol H, Michel FB: Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53: 61-66, 1993.
9. Niclinski J, Furman M, Chyczewski E, Chyczewski L, Rogowski F, Laudanski J: Diagnostic and prognostic value of the new tumor marker CYFRA 21-1 in patients with squamous cell lung cancer. Eur Respir j 8: 291-294, 1995.
10. Niclinski J, Furman M, Burzykowski T, Chyczewski L, Laudanski J, Chyczewski E, Rapellino M: Preoperative CYFRA 21-1 levels as a prognostic indicator in resected primary squamous lung cancer. Br J Cancer 74: 956-960, 1996.
11. Sobin LH, Hermanek P, Hutter RVP: TNM classification of malignant tumors. 4th edition. Geneva: International Union Against Cancer, 1987.
12. Nisman B, Lafair J, Heching N, Lyass O, Baras M, Peretz T, Barak V: Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma. Cancer 82: 1850-1859, 1998.
13. Cox DR: Regression models and life-tables. J R Stat Soc 34: 187-202, 1972.